Dr. Sid Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
About Dr. Sid Pharmaceutical
Dr. Sid Pharmaceutical Private Limited (DSPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 June 2020 (Four years and seven months 25 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Nehara, Manohar Chhabra, and Anita Chhabra serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U85200RJ2020PTC068993
- Company No.
068993
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Dr. Sid Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Nehara  | Director | 25-Feb-2022 | Current |
| Manohar Chhabra | Director | 06-Jun-2020 | Current |
| Anita Chhabra | Director | 02-Feb-2023 | Current |
Financial Performance of Dr. Sid Pharmaceutical.
Dr. Sid Pharmaceutical Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Dr. Sid Pharmaceutical?
In 2021, Dr. Sid Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Universe Precious Heaven Private LimitedRajendra Nehara is a mutual person
- Dr.Sid Laboratories Llp
Manohar Chhabra is a mutual person
- Tppl Pharmaceuticals Private Limited
Manohar Chhabra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr. Sid Pharmaceutical?
Dr. Sid Pharmaceutical has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Sid Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Sid Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.